{"id":"W4388694835","doi":"10.1016/j.jhep.2023.10.040","title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","year":2023,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Institute on Minority Health and Health Disparities; Genentech; Bayer HealthCare; G1 Therapeutics; MacroGenics; Tarveda Therapeutics; Pfizer; Incyte; Mersana Therapeutics; Les Laboratories Pierre Fabre; Ipsen; Jazz Pharmaceuticals; ViiV Healthcare; Agios Pharmaceuticals; Sirtex Medical; Cancer Research UK; Wellcome Trust; Exelixis; Revolution Medicines; Regeneron Pharmaceuticals; Astellas Pharma; Eisai; FibroGen; Servier; Gilead Sciences; Sanofi; GlaxoSmithKline; OncoMed Pharmaceutical; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Falk Foundation","keywords":"Medicine; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Incidence (geometry); Bevacizumab; Atezolizumab; Cohort; Cumulative incidence; Liver cancer; Cancer; Immunotherapy; Oncology; Nivolumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006007293,0.0001877355,0.0003655325,0.000570329,0.0002222972,0.0004795559,0.0002310788,0.0003096865,0.001271578],"category_scores_gemma":[0.00188892,0.0001247842,0.0004940602,0.0008220808,0.0002457089,0.0003298315,0.0003755927,0.0003840978,0.0001643039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004545602,"about_ca_system_score_gemma":0.0002705895,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001329533,"about_ca_topic_score_gemma":0.001435685,"domain_scores_codex":[0.9995381,0.0001152376,0.00006002489,0.0001186799,0.00007600545,0.00009190978],"domain_scores_gemma":[0.997804,0.000292611,0.001364953,0.00008030105,0.0001020769,0.000356136],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003322509,0.00002277182,0.998733,0.00000877911,0.00005090584,0.00004821907,0.00001977541,0.00005407598,0.000097277,0.000008995721,0.00004555062,0.000578368],"study_design_scores_gemma":[0.00002685172,0.0002443125,0.9990174,0.000004497791,0.00002511197,0.0003524961,0.00007056716,0.0001209401,0.00003973058,0.00001842191,0.00007673418,0.000002996247],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9993296,0.0002254019,0.00002977606,0.00002397293,0.000003360177,0.000005951556,0.0002221469,0.000001075138,0.0001587558],"genre_scores_gemma":[0.9994937,0.0000498818,0.00001528554,0.00001130172,0.000008704424,0.000005900469,0.0003771159,6.539136e-7,0.00003735447],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001329533,"threshold_uncertainty_score":0.004253864,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01122029119293104,"score_gpt":0.2627151369099966,"score_spread":0.2514948457170655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}